CVB homepage

Trending
New digital platform gets clinicians on the same page when treating heart attacks
Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis
FDA clears AI software for flagging signs of vascular disease
Hundreds of cardiologists incorrectly added to new mandatory payment model
Private equity unlikely to dominate cardiology despite hype
Newsweek ranked the 50 best heart hospitals in the world
EARLY TAVR update: New data highlight continued benefits of treating asymptomatic aortic stenosis

Philippe Généreux, MD, presented updated findings from one of cardiology's most closely watched trials at New York Valves 2026. 

FDA recall medical device recall product recall
Thousands of heart surgery kits recalled due to FDA quality concerns

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

the SKYWARD U.S. investigational device exemption (IDE) clinical program was launched to evaluate the Shockwave SkyRunner Carotid Intravascular Lithotripsy (IVL) System to break up carotid artery calcium prior to stenting.
Shockwave Medical announces new studies evaluating carotid IVL platform

Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease. 

Performing transcatheter aortic valve replacement (TAVR) with the J-Valve transcatheter heart valve (THV) may help limit the risk of coronary artery obstruction (CAO) in high-risk patients, according to a new study published in Clinical Interventions in Aging.[1]
TAVR with Edwards Lifesciences valve for severe AR linked to ‘encouraging’ data

All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in JSCAI.

heart drugs with stethoscope
Investigational heart drug for nonobstructive HCM one step closer to FDA approval

No drugs are currently approved by the FDA for the treatment of symptomatic, nonobstructive HCM. Could oral therapy ninerafaxstat be the first?

pills-384846_960_720.jpg
Chest pain drug lowers risk of kidney injury after PCI

Treating certain high-risk PCI patients with nicorandil before and after treatment can significantly reduce their risk of contrast-related injuries.

robot reviewing heart data
AI company founded by cardiologist gains FDA clearance, raises $8.5M

“We have colonoscopies, we have mammograms, but we have not had equivalents for most forms of heart disease,”  Pierre Elias, MD, Pathway Labs founder and CEO, explained.

Derek Pineda, FNP, CCRN, RCIS, FACC, with Mount Sinai Fuster Heart Hospital, explains the use of a digital app platform for STEMI team coordination that helped his health system improve STEMI outcomes.
New digital platform gets clinicians on the same page when treating heart attacks

One of the platform's biggest benefits is the rich clinical information it provides to all members of the care team.

heart doctor cardiologist
Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis

TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.

Innovation at work

Cardiovascular Business
Fewer biopsies, happier patients: Why molecular blood testing is a game-changer for managing heart transplant recipients

Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.  

In cooperation with CareDx

Around the web

Radiology Business
AI-powered brain tumor segmentation tool earns clearance in US
Health Exec
Clinicians are making more money despite stagnant reimbursement. Guess how?
Health Exec
Kentucky doc earns $3.5M judgment after seven-year court battle over complaint he was ‘on something’